Virginie Morel1, Gilles Duverlie1, Etienne Brochot2. 1. Department of Virology, Amiens University Medical Center, Amiens, France; Virology Research Unit, EA 4294, Jules Verne University of Picardie, Amiens, France. 2. Department of Virology, Amiens University Medical Center, Amiens, France; Virology Research Unit, EA 4294, Jules Verne University of Picardie, Amiens, France. Electronic address: etienne.brochot@u-picardie.fr.
Abstract
BACKGROUND: Simeprevir (Olysio(®)), a second-wave protease inhibitor recently approved for the treatment of chronic hepatitis C, is not indicated in patients with genotype 1a strain harboring the Q80K protease mutation. Phase 2 and 3 studies on this molecule mainly focused on North American patients and the prevalence of Q80K is particularly high in the USA (around 50%). The prevalence of this mutation in other parts of the world is currently unknown. OBJECTIVES: The purpose of our study was to perform a detection of this mutation in a single PCR technique and to study the prevalence of this Q80K mutation in a non U.S. population. We can thus estimate the proportion of HCV positive patients who can be treated with simeprevir. STUDY DESIGN: We conducted a meta-analysis of response rates in the presence or absence of this mutation in randomized trials and then describe a simple and reliable method to detect this mutation. We also examined bilirubin levels in our cohort of 95 HCV genotype 1a patients. RESULTS: Ten patients (10.5%) had a Q80K mutation and 12 patients exhibited bilirubin levels above the upper limit of normal at baseline. In our cohort, 21 patients (22%) were therefore ineligible for treatment with simeprevir. The prevalence of this mutation seems to be much lower in European patients. CONCLUSION: In conclusion, before considering treatment with simeprevir, physicians must be able to screen for the Q80K mutation.
BACKGROUND:Simeprevir (Olysio(®)), a second-wave protease inhibitor recently approved for the treatment of chronic hepatitis C, is not indicated in patients with genotype 1a strain harboring the Q80K protease mutation. Phase 2 and 3 studies on this molecule mainly focused on North American patients and the prevalence of Q80K is particularly high in the USA (around 50%). The prevalence of this mutation in other parts of the world is currently unknown. OBJECTIVES: The purpose of our study was to perform a detection of this mutation in a single PCR technique and to study the prevalence of this Q80K mutation in a non U.S. population. We can thus estimate the proportion of HCV positive patients who can be treated with simeprevir. STUDY DESIGN: We conducted a meta-analysis of response rates in the presence or absence of this mutation in randomized trials and then describe a simple and reliable method to detect this mutation. We also examined bilirubin levels in our cohort of 95 HCV genotype 1a patients. RESULTS: Ten patients (10.5%) had a Q80K mutation and 12 patients exhibited bilirubin levels above the upper limit of normal at baseline. In our cohort, 21 patients (22%) were therefore ineligible for treatment with simeprevir. The prevalence of this mutation seems to be much lower in European patients. CONCLUSION: In conclusion, before considering treatment with simeprevir, physicians must be able to screen for the Q80K mutation.
Authors: C K S Chui; W W Y Dong; J B Joy; A F Y Poon; W Y Dong; T Mo; C K Woods; C Beatty; H Hew; P R Harrigan; C J Brumme Journal: J Clin Microbiol Date: 2015-07-01 Impact factor: 5.948
Authors: André F Santos; Gonzalo Bello; Luãnna L Vidal; Suiane L Souza; Daiana Mir; Marcelo A Soares Journal: Sci Rep Date: 2016-08-17 Impact factor: 4.379
Authors: María Ángeles Jimenez-Sousa; Mónica Gutiérrez-Rivas; Alejandro Álvaro-Meca; Mónica García-Álvarez; P Richard Harrigan; Cesare Giovanni Fedele; Verónica Briz; Sonia Vázquez-Morón; Salvador Resino Journal: PLoS One Date: 2016-09-29 Impact factor: 3.240